Home ›
Entities
› academia
› Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Research article (Journal of Medical Economics, 2018) · cited 63× · AI/ML
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: an US societal perspective
Summary
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: an US societal perspective is a scholarly article[1].
Key Facts
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: an US societal perspective's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Retrieved May 24, 2026, from https://4ort.xyz/entity/estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients
MLA“Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients.
BibTeX@misc{4ortxyz_estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective}}, year = {2026}, url = {https://4ort.xyz/entity/estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective — https://4ort.xyz/entity/estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients (retrieved 2026-05-24)
